Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Pharmanet Development Grp (MM) Charts. Click Here for more Pharmanet Development Grp (MM) Charts.](/p.php?pid=staticchart&s=N%5EPDGI&p=8&t=15)
PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of
drug development services to branded pharmaceutical, biotechnology,
generic drug and medical device companies, today reported GAAP net
earnings from continuing operations for its fourth quarter 2006 of $3.5
million ($0.19 per diluted share) and for the full year ended December
31, 2006 of $6.1 million ($0.33 per diluted share).
"The fourth quarter and full year 2006 financial results demonstrate the
determination and commitment of the entire management team and all
PharmaNet Development Group employees to make continued progress while
overcoming the significant challenges of 2006,”
commented Jeffrey P. McMullen, president and chief executive officer.
Mr. McMullen added, “While addressing certain
events related to its discontinued operations, the Company continued to
build an organization and infrastructure that has achieved robust
revenue growth, strengthened its cash position and solidified its
financing allowing us to continue to build upon the momentum of the
early and late stage businesses and 2007 growth in backlog.”
Basis of presentation
Due to the Company's decision to discontinue certain operations in 2006,
all financial results for the periods presented reflect the Company's
continuing operations only, unless otherwise stated.
To better reflect ongoing operations for investors for the periods
presented, adjusted (non-GAAP) results are used throughout this press
release and the accompanying tables. The three months ended December 31,
2006 adjusted financial results exclude the following costs: a) a tax
valuation allowance of $2.6 million ($0.14 per diluted share) recorded
within earnings from continuing operations. The valuation allowance
results from the Company's 2006 domestic financial results (which have
created U.S. Net Operating Loss (NOL) carry-forwards of approximately
$40 million) and short-term projections for the geographic distribution
of income and losses which preclude realizing any current tax benefit
from certain of the Company’s domestic losses
until the Company restores its domestic profitability to utilize its
NOLs, b) non-cash amortization ($0.7 million) and c) non-cash
compensation expense resulting from the adoption of SFAS 123(R) ($0.1
million).
For the full year 2006, adjusted financial results exclude the following
costs: a) an impairment of goodwill related to the Clinical Pharmacology
Services (CPS), now named Specialty Pharmaceutical Services ($7.9
million), b) a non-cash financing charge related to the Company’s
credit facility ($1.2 million), c) non-cash amortization ($3.0 million),
d) a tax valuation allowance of $2.6 million ($0.14 per diluted share)
and e) non-cash compensation expense resulting from the adoption of SFAS
123(R) ($1.1 million). The Company adopted SFAS No. 123(R), Share Based
Payment, on January 1, 2006.
A reconciliation of GAAP results to adjusted (non-GAAP) results can be
found in the unaudited financial tables included in this press release.
A further explanation of the reasoning behind the use of non-GAAP
financial results can be found at the end of this press release.
Fourth Quarter 2006 Financial Summary
GAAP direct revenue, which does not include reimbursed out-of-pocket
expenses, increased 3.3% to $79.1 million in the fourth quarter 2006
compared to $76.6 million in the fourth quarter 2005 primarily due to
strong growth in the late stage segment offset by lower direct revenue
in the early stage segment. Compared to the previous quarter, fourth
quarter direct revenues increased 4.1% sequentially.
GAAP corporate SG&A expenses increased to $4.6 million in fourth
quarter 2006 compared to $4.2 million in fourth quarter 2005. Adjusted
corporate expenses, which exclude 123(R) expenses and non-recurring
legal and professional fees, increased to $4.3 million in the fourth
quarter 2006 from $3.5 million in the fourth quarter 2005 primarily
due to non-cash amortization of restricted stock units.
GAAP operating margin was 9.4% in the fourth quarter 2006 compared
with 12.5% in the fourth quarter 2005. Adjusted operating margin for
the fourth quarter 2006 decreased to 10.5% from 13.7% in the fourth
quarter 2005 primarily due to lower direct revenues in the early stage
segment, continued investment in early stage clinical and laboratory
facilities and higher corporate expenses.
GAAP net earnings were $3.5 million ($0.19 per diluted share) in the
fourth quarter 2006 compared to $6.1 million ($0.47 per diluted share)
in the fourth quarter 2005. Adjusted net earnings for the fourth
quarter 2006 were approximately $6.8 million ($0.36 per diluted share)
compared to $9.5 million ($0.51 per diluted share) for the fourth
quarter 2005 primarily due to lower profits in the early stage segment
and increased corporate expenses partly offset by increased
profitability in the late stage segment.
The Company’s backlog was $352.7 million at
December 31, 2006 compared to $357.0 million at September 30, 2006.
Backlog consists of anticipated direct revenue from signed contracts
and letters of intent that either have not started or are in process
and have not been completed. As of February 28, 2007, the Company’s
backlog grew to $417.8 million.
Cash, cash equivalents, and investments in marketable securities at
December 31, 2006 were $53.8 million compared to $53.8 million at
September 30, 2006 and $37.4 million at December 31, 2005.
Net cash used in continuing operations was $2.6 million. Capital
expenditures were $9.6 million (of which $5.8 million was invested in
the new Quebec City facility and reimbursed to the Company as part of
the sale lease back transaction announced in October 2006),
depreciation was $2.8 million and amortization was $0.7 million in the
fourth quarter 2006 compared with $6.7 million, $2.7 million and $0.9
million, respectively, in the fourth quarter 2005.
Net Days Sales Outstanding for continuing operations, which include
accounts receivable and unbilled services less current and long-term
advanced billings, were 34 days at December 31, 2006, reflecting a
more normalized level, compared with 23 days at September 30, 2006.
The Company’s effective tax rate in the
fourth quarter 2006 was 38.7% compared to 12.3% benefit in the fourth
quarter 2005. Excluding the valuation allowance described above, the
Company’s effective tax rate would have been
a benefit of 5.2% in the fourth quarter 2006.
During the fourth quarter 2006, the Company and its advisors
re-evaluated whether the Company would be able to realize the deferred
tax asset primarily created by the operations that were discontinued
during the second quarter 2006. After completing its analysis, the
Company determined that it is unlikely that the deferred tax asset
could be realized in the immediate future. As a result, the Company
recorded a tax valuation allowance of approximately $2.6 million in
continuing operations and $12.7 million in discontinued operations.
For the segment financial results provided below, the Company has
excluded an allocation of corporate expenses related to certain adjusted
selling, general and administrative ("SG&A") expenses.
Early Stage
PharmaNet Development Group, Inc.’s early
stage segment primarily includes the areas of Phase I clinical trials,
support services and bioanalytical services.
For the early stage segment, GAAP direct revenue, which does not include
reimbursed out-of-pocket expenses, was approximately $30.3 million in
the fourth quarter 2006 compared to $34.6 million in the fourth quarter
2005 and $25.9 million in the third quarter 2006. Direct revenues were
lower in the fourth quarter 2006 compared with the fourth quarter 2005
due to lower volume and pricing. The continued sequential improvement
resulted primarily from higher volume through the laboratories.
Early stage segment GAAP operating margins decreased to 17.3% in the
fourth quarter 2006 compared to 26.8% in the fourth quarter 2005. Early
stage segment adjusted operating margins decreased to 17.7% in the
fourth quarter 2006 compared to 27.4% in the fourth quarter 2005
primarily due to lower direct revenues.
The backlog for the early stage segment increased to $43.1 million from
$37.6 million reported at September 30, 2006 due to improving visibility
in new generic, Phase I and bioanalytical business. As of February 28,
2007, the early stage backlog is $40.5 million.
The construction plan is on schedule for the new Quebec City facility
that will replace the two existing facilities that comprise Anapharm
headquarters. Approximately 90% of the building and tenant improvements
are completed. The Company expects to begin occupying the facility
during March 2007 and complete the move by the end of May 2007.
The Company is completing the leasehold improvements at its Toronto site
which will house clinical facilities. Currently, these improvements are
expected to be completed by early April 2007. The Company expects to
open the Toronto facility mid-year 2007.
Capital expenditures for the Quebec City facility were $5.8 million in
the fourth quarter 2006 and $13.3 million for the full year (these
amounts have been reimbursed to the Company through the sale lease back
transaction). The Company plans to invest approximately $2.1 million
(which will not be reimbursed) in 2007 to complete the fit out of the
facility.
Effective January 1, 2007, the Company will begin reporting its
Specialty Pharmaceutical Services business in the late stage segment
rather than the early stage segment. Direct revenues were approximately
$3.7 million in 2006.
Late Stage
PharmaNet Development Group, Inc.’s late
stage segment primarily conducts Phase II through IV clinical trials,
data management and biostatistics, medical and scientific affairs,
regulatory affairs and submissions, and provides software tools and
services for use in clinical trials.
For the late stage segment, GAAP direct revenue, which does not include
reimbursed out-of-pocket expenses, were $48.8 million in the fourth
quarter 2006 compared to $41.9 million in the fourth quarter 2005.
Late stage segment GAAP operating margins were 13.9% in the fourth
quarter 2006 compared to 10.8% in the fourth quarter 2005. Late stage
segment adjusted operating margins were 15.0% in the fourth quarter 2006
compared to 12.5% in the fourth quarter 2005 primarily due to higher
volume.
The backlog for the late stage segment was $309.6 million at December
31, 2006 compared to $319.4 million at September 30, 2006. As of
February 28, 2007, the late stage backlog was $377.3 million.
Full Year 2006 Financial Summary
Full year 2006 GAAP direct revenue, which does not include reimbursed
out-of-pocket expenses, increased 12.2% to $302.4 million compared to
$269.6 million in 2005 primarily due to strong growth in the late
stage segment offset by lower direct revenue in the early stage
segment.
GAAP corporate SG&A expenses increased to $21.0 million in 2006
compared to $12.3 million in 2005 primarily due to additional
professional, legal and accounting fees ($3.0 million), non-cash
compensation expense resulting from the adoption of SFAS 123(R) ($1.1
million), 2005 management bonuses not paid out ($1.0 million),
amortization of RSUs ($2.0 million) and additional insurance, travel
expense and salaries ($1.7 million).
GAAP operating margin was 4.3% in 2006 compared with 11.1% in 2005.
Adjusted operating margin for 2006 decreased to 8.3% from 12.5% in
2005 primarily due to lower direct revenues in the early stage
segment, continued investment in early stage clinical and laboratory
facilities and higher corporate expenses.
GAAP net earnings were $6.1 million ($0.33 per diluted share) in 2006
compared to $17.2 million ($0.94 per diluted share) in 2005. Adjusted
net earnings for 2006 were approximately $17.4 million ($0.94 per
diluted share) compared to $23.3 million ($1.27 per diluted share) for
2005 primarily due to lower profits in the early stage segment and
increased corporate expenses partly offset by increased profitability
in the late stage segment.
Discontinued operations
The Company has a remaining $3.3 million balance of expected cash costs
relating to discontinued operations for completion of the site clean-up,
severance related costs and contracted services. The Company is
assessing its options with respect to the sale of the land relating to
its discontinued operations.
The Company also recorded a $12.7 million ($0.68 per diluted share)
valuation allowance within the loss from discontinued operations, net of
tax, to write down the value of certain U.S. non-cash deferred tax
assets.
Guidance
For continuing operations in 2007, the Company expects:
direct revenues to be in the range of $334 –
$339 million, with approximately one third of the revenues coming from
the early stage segment and two thirds of the revenues coming from the
late stage segment,
Adjusted EBIT margin to be in the range of 9.5% - 9.8%,
corporate expenses to be approximately $20 –
$21 million,
adjusted pre-tax earnings to be in the range of $26 –
$28 million,
GAAP fully diluted EPS of $0.93 - $1.08 and adjusted fully diluted EPS
of $1.06 – $1.21,
capital expenditures to be in the range of $16 –
$18 million, of which $2.1 million will be used to complete the
expansion in Quebec City,
depreciation to be in the range of $12 –
$13 million,
amortization to be approximately $2.8 million, and
tax rate to be in the range of 15% - 20%.
The Company’s 2007 guidance takes into
consideration the impact of the recently recorded valuation allowance on
the tax rate and future 2007 diluted earnings per share.
Conference Call and Webcast
A conference call and webcast to discuss fourth quarter and full year
2006 financial results will be held on Thursday, March 1, 2007 at 8:30
a.m., Eastern Time.
Dial-in:
(866) 713-8563 for U.S.
(617) 597-5311 for International
Pass code: 65023741
Dial-in Replay:
(888) 286-8010 for U.S.
(617) 801-6888 for International
Pass code: 53682689
The dial-in replay will be available approximately
two hours after the call through Thursday, March 8,
2007.
Webcast:
Please visit www.pharmanet.com
and select the
investor tab to access the webcast or alternatively,
you may click on the following hyperlink:
http://ir.pharmanet.com/phoenix.zhtml?c=124176&p=IROL-Guestbook&UniqueId=1453069&mp=irol-eventdetails&mpdp=EventId~1453069!WebCastId~608399!StreamId~831375&pp=IROL-BasicWebCast&ppdp=EventId~1453069!WebCastId~608399!StreamId~831375&pph=339&ppw=270&rdu=&rdt=&upv=
(Due to its length, this URL may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one
exists.)
The archived webcast will be available for
approximately thirty (30) days following the
conference call.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, which exclude,
among other items, amortization of acquisition-related intangible
assets, non-recurring charges related to financing, non-cash
compensation expense resulting from SFAS 123(R) and non-cash impairment
charges. PDGI excludes these items from the non-GAAP financial measures
because they are outside of its operations and are a useful indicator,
which allows management to monitor PDGI’s
underlying business performance.
Non-GAAP results also allow investors to compare the reported GAAP
results and the non-GAAP First Call consensus estimate and to compare
the Company’s operations against the
financial results of other companies in the industry. The non-GAAP
financial measures included in this press release should not be
considered superior to or a substitute for results of operations
prepared in accordance with GAAP. Reconciliations of the non-GAAP
financial measures used in this press release to the most directly
comparable GAAP financial measures are set forth in the text of, and the
accompanying tables to, this press release, and can also be found on the
Company’s website.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, a global, drug development company,
provides a comprehensive range of services to the pharmaceutical,
biotechnology, generic drug, and medical device industries. The Company
offers clinical-development solutions including early and late stage
consulting services, Phase I clinical studies and bioanalytical
analyses, and Phase II, III and IV clinical development programs. With
approximately 2,200 employees and more than 35 facilities throughout the
world, PharmaNet is a recognized leader in outsourced clinical
development. For more information, please visit our website at www.pharmanet.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally, words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause or
contribute to such differences include, but are not limited to, industry
trends and information; the Company's ability to determine its
impairment charges and costs of discontinued operations; whether the
Company will achieve its estimated value relating to discontinued
operations; developments with respect to the SEC's inquiry and
securities class action lawsuits and derivative lawsuits; the Company’s
ability to successfully achieve and manage the technical requirements of
specialized clinical trial services, while complying with applicable
rules and regulations; regulatory changes; changes affecting the
clinical research industry; a reduction of outsourcing by pharmaceutical
and biotechnology companies; the Company’s
ability to compete internationally in attracting clients in order to
develop additional business; the Company’s
evaluation of its backlog and the potential cancellation of contracts;
its ability to retain and recruit new employees; its clients' ability to
provide the drugs and medical devices used in its clinical trials; the
Company’s future stock price; its assessment
of its effective tax rate and tax allowance; the Company’s
financial guidance; the future effective tax rate; our anticipated
capital expenditures; our costs associated with compliance of Section
404 of the Sarbanes-Oxley Act; the impact of foreign currency
transaction costs and the effectiveness of any hedging strategies that
we implement; and the national and international economic climate as it
affects drug development operations.
Further information can be found in the Company’s
risk factors contained in its Annual Report on Form 10-K for the year
ended December 31, 2005, which were originally filed as SFBC
International, Inc. (NASDAQ: SFCC) and its most recent Quarterly Report
on Form 10-Q. The Company does not undertake to update the disclosures
made herein, and you are urged to read our filings with the Securities
and Exchange Commission.
PharmaNet Development Group, Inc. and Subsidiaries
Statement of Operations- (Unaudited)
For the Three Months Ended December 31, 2006
(Unaudited)
(As Revised)
3 Months
3 Months
Ended
Ended
December 31, 2006
December 31, 2005
REVENUE
Direct revenue
79,104,468
76,568,709
Reimbursed out-of-pockets
24,451,526
26,543,635
TOTAL REVENUE
103,555,994
103,112,344
COSTS AND EXPENSES
Direct costs
45,672,200
43,810,787
Reimbursable out-of-pocket expenses
24,451,526
26,543,635
Selling, general and administrative expenses
26,008,738
23,179,905
Impairment of goodwill
-
-
Impairment of long-lived assets
-
-
TOTAL COSTS AND EXPENSES
96,132,464
93,534,327
EARNINGS FROM CONTINUING OPERATIONS
7,423,530
9,578,017
OTHER INCOME (EXPENSE)
Interest income
585,711
196,005
Interest expense
(1,681,962)
(1,672,135)
Foreign exchange transaction loss, net
(339,804)
(170,849)
TOTAL OTHER INCOME (EXPENSE)
(1,436,055)
(1,646,979)
EARNINGS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
5,987,475
7,931,038
Income tax (benefit)
2,316,900
(977,718)
EARNINGS FROM CONTINUING OPERATIONS BEFORE MINORITY INTEREST IN
JOINT VENTURE
3,670,575
8,908,756
Minority interest in joint venture
173,729
185,546
NET EARNINGS FROM CONTINUING OPERATIONS
3,496,846
8,723,210
Loss from discontinued operations, net of tax
(15,409,221)
(25,249,699)
NET LOSS
(11,912,375)
(16,526,489)
BASIC EARNINGS (LOSS) PER SHARE:
Continuing operations
$0.19
$0.48
Discontinued operations
($0.84)
($1.39)
Net loss
($0.65)
($0.91)
DILUTED EARNINGS (LOSS) PER SHARE:
Continuing operations
$0.19
$0.47
Discontinued operations
($0.83)
($1.35)
Net loss
($0.64)
($0.88)
SHARES USED IN COMPUTING EPS:
Basic
18,438,517
18,247,667
Diluted
18,653,190
18,753,018
PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Operating Margin for Continuing Operations
to Non GAAP Operating Margins for Continuing Operations
For the Three and Twelve Months Ended December 31, 2006 and 2005
Three Months Ended
Twelve Months Ended
December 31, 2006
December 31, 2006
2006
2005
2006
2005
DIRECT REVENUE
79,104,468
76,568,709
302,384,611
269,622,415
EARNINGS FROM CONTINUING OPERATIONS GAAP
7,423,530
9,578,017
13,005,918
29,844,155
OPERATING MARGIN GAAP
9.4%
12.5%
4.3%
11.1%
ADD BACK:
FAS 123R expense
149,061
-
1,107,576
-
Amortization of acquisition related intangibles
708,517
901,290
2,982,876
3,932,607
Impairment of goodwill
-
-
7,873,000
-
NON GAAP OPERATING EARNINGS
8,281,108
10,479,307
24,969,370
33,776,762
NON GAAP OPERATING MARGIN
10.5%
13.7%
8.3%
12.5%
Statement of Operations- (Unaudited)
For the Twelve Months Ended December 31, 2006
(Unaudited)
(As Revised)
12 Months
12 Months
Ended
Ended
December 31, 2006
December 31, 2005
REVENUE
Direct revenue
302,384,611
269,622,415
Reimbursed out-of-pockets
104,570,757
91,883,814
TOTAL REVENUE
406,955,368
361,506,229
COSTS AND EXPENSES
Direct costs
181,556,250
155,900,530
Reimbursable out-of-pocket expenses
104,570,757
91,883,814
Selling, general and administrative expenses
99,949,443
83,877,730
Impairment of goodwill
7,873,000
-
Impairment of long-lived assets
-
-
TOTAL COSTS AND EXPENSES
393,949,450
331,662,074
EARNINGS FROM CONTINUING OPERATIONS
13,005,918
29,844,155
OTHER INCOME (EXPENSE)
Interest income
1,635,771
890,646
Interest expense
(8,114,581)
(12,016,506)
Foreign exchange transaction loss, net
(3,341,930)
(849,108)
TOTAL OTHER INCOME (EXPENSE)
(9,820,740)
(11,974,968)
EARNINGS FROM CONTINUING OPERATIONS
3,185,178
17,869,187
BEFORE INCOME TAXES
Income tax (benefit)
(3,557,552)
153,606
EARNINGS FROM CONTINUING OPERATIONS
BEFORE MINORITY INTEREST IN JOINT VENTURE
6,742,730
17,715,581
Minority interest in joint venture
690,527
552,401
NET EARNINGS FROM CONTINUING OPERATIONS
6,052,203
17,163,180
Loss from discontinued operations, net of tax
(42,076,773)
(12,384,375)
NET (Loss) Earnings
(36,024,570)
4,778,805
BASIC EARNINGS (LOSS) PER SHARE:
Continuing operations
$0.33
$0.97
Discontinued operations
($2.31)
($0.70)
Net loss
($1.98)
$0.27
DILUTED EARNINGS (LOSS) PER SHARE:
Continuing operations
$0.33
$0.94
Discontinued operations
($2.28)
($0.68)
Net loss
($1.95)
$0.26
SHARES USED IN COMPUTING EPS:
Basic
18,221,418
17,701,810
Diluted
18,447,048
18,356,030
PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Reconciliation of GAAP Net Earnings for Continuing Operations to
Non GAAP Net Earnings from Continuing Operations
For the Three and Twelve Months Ended December 31, 2006 and 2005
Three Months Ended
Twelve Months Ended
December 31, 2006
December 31, 2006
2006
2005
2006
2005
Net earnings from continuing operations GAAP
3,496,846
8,723,210
6,052,203
17,163,180
Add: Impairment of goodwill
-
-
7,873,000
-
Add: Non-recurring charge related to financing
-
-
1,214,306
3,278,279
Add: Non-cash compensation from the
149,061
1,107,576
adoption of SFAS 123R
Add: Non-cash amortization
708,517
901,290
2,982,876
3,932,607
Subtotal
4,354,424
9,624,500
19,229,961
24,374,066
Less: Tax effect of non-GAAP adjustments
221,955
148,348
4,429,204
1,057,778
Add : Tax valuation allowance
2,629,968
-
2,629,968
-
Non-GAAP net earnings
6,762,437
9,476,152
17,430,725
23,316,288
Diluted non-GAAP net earnings per share
$ 0.36
$ 0.51
$ 0.94
$ 1.27
Number of shares used in computing diluted
non-GAAP earnings per share
18,653,190
18,753,018
18,447,048
18,356,030
Summary of Operations of Early and Late Stage Clinical
Development Segments For the Three and Twelve Months Ended
December 31, 2006 and 2005
Three Months Ended
Twelve Months Ended
December
December
EARLY CLINICAL DEVELOPMENT
2006
2005
%
variation
2006
2005
%
variation
Direct revenues
30,283,571
34,630,401
-12.6%
106,975,586
112,093,006
-4.6%
GAAP operating earnings
5,237,538
9,277,492
(1)
-43.5%
4,860,397
24,876,063
(1)
-80.5%
Amortization of intangibles
133,716
226,983
-41.1%
683,675
1,244,341
-45.1%
Non-GAAP operating earnings
5,371,254
9,504,475
-43.5%
5,544,072
26,120,404
-78.8%
GAAP operating Margin
17.3%
26.8%
4.5%
22.2%
Non-GAAP operating margin
17.7%
27.4%
5.2%
23.3%
Three Months Ended
Twelve Months Ended
December
December
LATE CLINICAL DEVELOPMENT
2006
2005
%
variation
2006
2005
%
variation
Direct revenues
48,820,897
41,938,308
16.4%
195,409,025
157,529,409
24.0%
GAAP operating earnings
6,771,250
4,547,140
(1)
48.9%
29,189,705
17,242,117
(1)
69.3%
Amortization of intangibles
574,800
674,307
-14.8%
2,299,200
2,688,266
-14.5%
Non-GAAP operating earnings
7,346,050
5,221,447
40.7%
31,488,905
19,930,383
58.0%
GAAP operating Margin
13.9%
10.8%
14.9%
10.9%
Non-GAAP operating margin
15.0%
12.5%
16.1%
12.7%
(1) Prior year results have been reclassified, to conform to current
year treatment, to exclude foreign exchange gain or loss
PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES
Selected Consolidated Balance Sheet Information
December 31, 2006 and 2005
The allocation of assets and liabilities between continuing and
discontinued operations, in this selected balance sheet
information is preliminary and may change upon the company's
filing of its from 10-K for the period ended December 31, 2006
(Unaudited)
(As Revised)
December 31,
December 31,
2006
2005
ASSETS
Cash, equivalents and investments in marketable securities from
continuing operations
53,754,183
37,413,251
Cash, equivalents and investments in marketable securities from
discontinued operations
-
1,421,451
Total cash, equivalents, and investments in marketable securities
53,754,183
38,834,702
Accounts receivable from continuing operations
109,187,958
91,446,190
Accounts receivable from discontinued operations
3,572,556
26,425,479
Accounts receivable
112,760,514
117,871,669
Current assets from continuing operations
189,735,483
148,692,703
Current assets from discontinued operations
3,572,556
29,335,006
Total current assets
193,308,039
178,027,709
Fixed assets from continuing operations
68,085,924
48,563,461
Fixed assets held available for sale from discontinued operations
3,286,619
24,701,651
Total fixed assets
71,372,543
73,265,112
Total assets from continuing operations
576,358,562
514,328,567
Total assets from discontinued operations
6,859,175
58,208,529
Total assets
583,217,737
572,537,096
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities from continuing operations
134,556,549
120,493,672
Current liabilities from discontinued operations
6,144,643
5,940,389
Total current liabilities
140,701,192
126,434,061
Total liabilities from continuing operations
317,907,226
284,315,108
Total liabilities from discontinued operations
6,144,643
5,940,389
Total liabilities
324,051,869
290,255,497
Stockholders' equity
259,165,868
282,281,599
Total liabilities and stockholders' equity
583,217,737
572,537,096